Among Japanese patients , median overall survival was not estimable ( 95 % confidence interval , 7.4 months-not estimable ) with axitinib/gemcitabine ( n = 58 ) and 9.9 months ( 95 % confidence interval , 7.4-10 .5 ) with placebo/gemcitabine ( n = 56 ) ( hazard ratio 1.093 [ 95 % confidence interval , 0.525-2 .274 ] ) .